Allelic loss on chromosome 7q in ovarian adenocarcinomas: two critical regions and a rearrangement of the PLANH1 locus. 1996

J Kerr, and J A Leary, and T Hurst, and Y C Shih, and T M Antalis, and M Friedlander, and E Crawford, and S K Khoo, and B Ward, and G Chenevix-Trench
Queensland Cancer Fund Research Unit, The Queensland Institute of Medical Research, Brisbane, Australia.

The presence of a tumour suppressor gene on chromosome 7q is indicated by cytogenetic, loss of heterozygosity (LOH) and chromosome transfer studies. One candidate gene in this region is Plasminogen Activator Inhibitor-1 (PAI-1). The PAI-1 gene product is involved in proteolysis and may therefore influence tumour spread and invasion. We have analysed a series of 139 ovarian epithelial tumours at four loci in the region 7q21-q31 which includes the PAI-1 gene. The highest rates of loss were found in malignant tumours (FIGO stages I-IV) at markers D7S471 (38%, 20/52 informative cases) and D7S522 (34%, 15/44). No loss was seen in benign tumours and only one out of 27 (4%) informative LMP tumours demonstrated LOH. The smallest region of overlap (SRO) lies between D7S471 and PAI-1. We also identified a rearrangement in one tumour in the PAI-1 gene, suggesting that this may be the inactivated gene in this region. In addition LOH at the more distal marker, D7S522, which lies outside the SRO, shows significant association with stage (P=0.0343) and with LOH on chromosome 13 (P=0.0024). This is in contrast to all other markers examined. These data suggest the presence of two critical regions on 7q which may be important in subsets of epithelial ovarian tumours.

UI MeSH Term Description Entries
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D002872 Chromosome Deletion Actual loss of portion of a chromosome. Monosomy, Partial,Partial Monosomy,Deletion, Chromosome,Deletions, Chromosome,Monosomies, Partial,Partial Monosomies
D002897 Chromosomes, Human, Pair 7 A specific pair of GROUP C CHROMOSOMES of the human chromosome classification. Chromosome 7
D005260 Female Females
D006579 Heterozygote An individual having different alleles at one or more loci regarding a specific character. Carriers, Genetic,Genetic Carriers,Carrier, Genetic,Genetic Carrier,Heterozygotes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000483 Alleles Variant forms of the same gene, occupying the same locus on homologous CHROMOSOMES, and governing the variants in production of the same gene product. Allelomorphs,Allele,Allelomorph
D017395 Plasminogen Activator Inhibitor 1 A member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activators. PAI-1,SERPINE1 Protein,Serpin E1,Type 1 Plasminogen Activator Inhibitor,E1, Serpin,Protein, SERPINE1

Related Publications

J Kerr, and J A Leary, and T Hurst, and Y C Shih, and T M Antalis, and M Friedlander, and E Crawford, and S K Khoo, and B Ward, and G Chenevix-Trench
September 1998, Oncogene,
J Kerr, and J A Leary, and T Hurst, and Y C Shih, and T M Antalis, and M Friedlander, and E Crawford, and S K Khoo, and B Ward, and G Chenevix-Trench
September 1999, Japanese journal of cancer research : Gann,
J Kerr, and J A Leary, and T Hurst, and Y C Shih, and T M Antalis, and M Friedlander, and E Crawford, and S K Khoo, and B Ward, and G Chenevix-Trench
August 1996, Cancer research,
J Kerr, and J A Leary, and T Hurst, and Y C Shih, and T M Antalis, and M Friedlander, and E Crawford, and S K Khoo, and B Ward, and G Chenevix-Trench
April 1993, International journal of cancer,
J Kerr, and J A Leary, and T Hurst, and Y C Shih, and T M Antalis, and M Friedlander, and E Crawford, and S K Khoo, and B Ward, and G Chenevix-Trench
February 2009, Cancer genetics and cytogenetics,
J Kerr, and J A Leary, and T Hurst, and Y C Shih, and T M Antalis, and M Friedlander, and E Crawford, and S K Khoo, and B Ward, and G Chenevix-Trench
July 1995, Genomics,
J Kerr, and J A Leary, and T Hurst, and Y C Shih, and T M Antalis, and M Friedlander, and E Crawford, and S K Khoo, and B Ward, and G Chenevix-Trench
January 1986, Cytogenetics and cell genetics,
J Kerr, and J A Leary, and T Hurst, and Y C Shih, and T M Antalis, and M Friedlander, and E Crawford, and S K Khoo, and B Ward, and G Chenevix-Trench
January 2005, Cancer genetics and cytogenetics,
J Kerr, and J A Leary, and T Hurst, and Y C Shih, and T M Antalis, and M Friedlander, and E Crawford, and S K Khoo, and B Ward, and G Chenevix-Trench
November 1995, Cancer research,
J Kerr, and J A Leary, and T Hurst, and Y C Shih, and T M Antalis, and M Friedlander, and E Crawford, and S K Khoo, and B Ward, and G Chenevix-Trench
June 1998, Cancer research,
Copied contents to your clipboard!